



Long Acting Opioids Utilization 2012 Q2 & 2012 Q3


**Total Claims
2012 Quarter 2**




**Total Claims
2012 Quarter 3**



**Total Amount Paid
2012 Quarter 2**



**Total Amount Paid
2012 Quarter 3**



Long Acting Opioids Utilization 2012 Q2 & 2012 Q3

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
April 2012	AVINZA CAP 60MG	2	60	60	\$4.76	\$255.54	Avinza
April 2012	DURAGESIC DIS 12MCG/HR	1	10	30	\$4.76	\$205.68	Fentanyl Patches
April 2012	FENTANYL DIS 12MCG/HR	16	90	255	\$42.84	\$616.23	Fentanyl Patches
April 2012	DURAGESIC DIS 25MCG/HR	12	125	335	\$52.36	\$2,845.56	Fentanyl Patches
April 2012	FENTANYL DIS 25MCG/HR	45	384	1,040	\$142.80	\$1,809.59	Fentanyl Patches
April 2012	DURAGESIC DIS 50MCG/HR	13	118	309	\$61.88	\$5,295.65	Fentanyl Patches
April 2012	FENTANYL DIS 50MCG/HR	46	410	1,136	\$90.44	\$2,149.37	Fentanyl Patches
April 2012	DURAGESIC DIS 75MCG/HR	14	147	391	\$61.88	\$9,994.27	Fentanyl Patches
April 2012	FENTANYL DIS 75MCG/HR	41	308	838	\$76.16	\$1,960.61	Fentanyl Patches
April 2012	DURAGESIC DIS 100MCG/H	23	209	530	\$109.48	\$18,875.34	Fentanyl Patches
April 2012	FENTANYL DIS 100MCG/H	42	431	892	\$90.44	\$3,990.41	Fentanyl Patches
April 2012	KADIAN CAP 10MG CR	2	120	60	\$9.52	\$550.22	Kadian
April 2012	KADIAN CAP 20MG CR	7	450	210	\$23.80	\$1,267.54	Kadian
April 2012	MORPHINE SUL CAP 20MG ER	2	90	60	\$0.00	\$2.20	Kadian
April 2012	KADIAN CAP 30MG CR	10	510	300	\$47.60	\$2,708.25	Kadian
April 2012	MORPHINE SUL CAP 30MG ER	4	240	105	\$4.76	\$286.50	Kadian
April 2012	KADIAN CAP 50MG CR	11	600	330	\$47.60	\$4,807.29	Kadian
April 2012	MORPHINE SUL CAP 50MG ER	4	240	120	\$14.28	\$1,349.20	Kadian
April 2012	KADIAN CAP 60MG CR	9	510	270	\$33.32	\$4,180.52	Kadian
April 2012	MORPHINE SUL CAP 60MG ER	3	180	90	\$9.52	\$524.43	Kadian
April 2012	KADIAN CAP 80MG CR	9	540	255	\$42.84	\$7,667.59	Kadian
April 2012	KADIAN CAP 100MG CR	12	710	355	\$47.60	\$9,785.05	Kadian
April 2012	MORPHINE SUL CAP 100MG ER	2	120	60	\$4.76	\$1,401.77	Kadian
April 2012	KADIAN CAP 200MG CR	6	332	166	\$28.56	\$11,847.79	Kadian
April 2012	METHADONE CON 10MG/ML	1	30	3	\$0.00	\$3.30	Methadone Concentrate
April 2012	METHADOSE CON 10MG/ML	1	42	3	\$4.76	\$8.49	Methadone Concentrate
April 2012	METHADONE SOL 5MG/5ML	3	176	43	\$14.28	\$27.78	Methadone Solution
April 2012	METHADONE SOL 10MG/5ML	2	57	29	\$9.52	\$17.89	Methadone Solution
April 2012	METHADONE TAB 5MG	34	2,219	672	\$133.71	\$264.95	Methadone Tab
April 2012	METHADONE TAB 10MG	440	80,582	11,871	\$1,628.79	\$8,887.35	Methadone Tab
April 2012	METHADOSE TAB 10MG	2	630	57	\$9.52	\$83.00	Methadone Tab
April 2012	MORPHINE SUL TAB 15MG ER	356	19,686	8,607	\$1,368.70	\$10,438.00	MS Contin
April 2012	MORPHINE SUL TAB 30MG ER	417	25,217	10,809	\$1,532.77	\$18,820.39	MS Contin
April 2012	MS CONTIN TAB 30MG CR	1	30	30	\$0.00	\$3.30	MS Contin
April 2012	MORPHINE SUL TAB 60MG ER	217	14,933	6,160	\$709.24	\$11,516.04	MS Contin
April 2012	MORPHINE SUL TAB 100MG ER	113	7,784	3,094	\$390.32	\$17,262.89	MS Contin
April 2012	ORAMORPH SR TAB 100MG	1	60	20	\$4.76	\$5.36	MS Contin
April 2012	MORPHINE SUL TAB 200MG ER	7	426	183	\$28.56	\$1,943.96	MS Contin
April 2012	NUCYNTA ER TAB 50MG	3	240	90	\$14.28	\$609.15	Nucynta ER
April 2012	NUCYNTA ER TAB 100MG	4	190	95	\$14.28	\$704.55	Nucynta ER
April 2012	NUCYNTA ER TAB 150MG	2	120	60	\$9.52	\$717.00	Nucynta ER
April 2012	NUCYNTA ER TAB 200MG	1	60	30	\$4.76	\$455.19	Nucynta ER
April 2012	OPANA ER TAB 10MG	4	240	120	\$14.28	\$683.25	Opana ER
April 2012	OPANA ER TAB 15MG	1	56	28	\$0.00	\$3.30	Opana ER
April 2012	OPANA ER TAB 20MG	5	420	150	\$19.04	\$2,383.62	Opana ER
April 2012	OPANA ER TAB 30MG	6	360	165	\$23.80	\$2,859.35	Opana ER
April 2012	OPANA ER TAB 40MG	19	1,274	531	\$76.16	\$12,827.69	Opana ER
April 2012	OPANA ER TAB 10MG	4	240	120	\$4.76	\$236.55	Opana ER

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
April 2012	OPANA ER TAB 20MG	6	360	180	\$23.80	\$1,994.85	Opana ER
April 2012	OPANA ER TAB 30MG	6	420	178	\$23.80	\$3,142.57	Opana ER
April 2012	OPANA ER TAB 40MG	18	1,500	540	\$57.12	\$14,124.73	Opana ER
April 2012	OXYCONTIN TAB 10MG CR	19	942	384	\$42.84	\$1,055.97	Oxycontin
April 2012	OXYCONTIN TAB 15MG CR	5	300	150	\$9.52	\$389.84	Oxycontin
April 2012	OXYCONTIN TAB 20MG CR	33	2,210	955	\$99.96	\$5,225.11	Oxycontin
April 2012	OXYCONTIN TAB 30MG CR	15	930	440	\$38.08	\$2,740.82	Oxycontin
April 2012	OXYCONTIN TAB 40MG CR	55	3,998	1,608	\$171.36	\$19,829.39	Oxycontin
April 2012	OXYCONTIN TAB 60MG CR	22	1,796	659	\$61.88	\$8,977.64	Oxycontin
April 2012	OXYCONTIN TAB 80MG CR	76	6,254	2,184	\$271.32	\$59,590.62	Oxycontin
April 2012	TRAMADOL HCL TAB 100MG ER	4	270	120	\$14.28	\$519.46	Tramadol HCL
April 2012	TRAMADOL HCL TAB 200MG ER	6	210	180	\$19.04	\$703.30	Tramadol HCL
April 2012	TRAMADOL HCL TAB 100MG ER	1	30	30	\$4.76	\$112.67	Tramadol HCL
May 2012	AVINZA CAP 30MG	1	30	30	\$4.76	\$132.20	Avinza
May 2012	AVINZA CAP 60MG	1	30	30	\$0.00	\$3.30	Avinza
May 2012	FENTANYL DIS 12MCG/HR	17	95	285	\$19.04	\$533.88	Fentanyl Patches
May 2012	DURAGESIC DIS 25MCG/HR	18	190	489	\$80.92	\$3,299.44	Fentanyl Patches
May 2012	FENTANYL DIS 25MCG/HR	74	582	1,613	\$138.04	\$1,893.98	Fentanyl Patches
May 2012	DURAGESIC DIS 50MCG/HR	24	232	637	\$114.24	\$8,101.99	Fentanyl Patches
May 2012	FENTANYL DIS 50MCG/HR	65	391	1,068	\$104.72	\$1,910.41	Fentanyl Patches
May 2012	DURAGESIC DIS 75MCG/HR	15	175	410	\$71.40	\$9,853.14	Fentanyl Patches
May 2012	FENTANYL DIS 75MCG/HR	48	391	1,056	\$109.48	\$3,751.31	Fentanyl Patches
May 2012	DURAGESIC DIS 100MCG/H	18	185	485	\$85.68	\$10,100.07	Fentanyl Patches
May 2012	FENTANYL DIS 100MCG/H	39	309	774	\$71.40	\$2,488.33	Fentanyl Patches
May 2012	KADIAN CAP 10MG CR	3	150	75	\$14.28	\$690.16	Kadian
May 2012	KADIAN CAP 20MG CR	3	93	63	\$14.28	\$477.22	Kadian
May 2012	MORPHINE SUL CAP 20MG ER	3	120	90	\$4.76	\$227.19	Kadian
May 2012	KADIAN CAP 30MG CR	14	648	384	\$61.88	\$3,421.86	Kadian
May 2012	MORPHINE SUL CAP 30MG ER	3	210	90	\$4.76	\$285.40	Kadian
May 2012	KADIAN CAP 50MG CR	6	320	170	\$28.56	\$2,923.76	Kadian
May 2012	MORPHINE SUL CAP 50MG ER	4	240	120	\$9.52	\$880.24	Kadian
May 2012	KADIAN CAP 60MG CR	12	720	360	\$47.60	\$6,546.02	Kadian
May 2012	MORPHINE SUL CAP 60MG ER	3	180	90	\$9.52	\$524.43	Kadian
May 2012	KADIAN CAP 80MG CR	6	350	160	\$28.56	\$5,077.37	Kadian
May 2012	KADIAN CAP 100MG CR	14	778	404	\$47.60	\$10,179.43	Kadian
May 2012	MORPHINE SUL CAP 100MG ER	1	30	30	\$0.00	\$1.10	Kadian
May 2012	KADIAN CAP 200MG CR	4	208	104	\$19.04	\$7,622.93	Kadian
May 2012	METHADONE TAB 5MG	55	3,022	894	\$198.17	\$356.00	Methadone Tab
May 2012	METHADONE TAB 10MG	498	84,166	12,632	\$1,859.41	\$9,813.74	Methadone Tab
May 2012	METHADONE SOL 5MG/5ML	4	284	92	\$19.04	\$41.62	Methadone Solution
May 2012	METHADONE SOL 10MG/5ML	2	8	19	\$9.52	\$10.70	Methadone Solution
May 2012	MORPHINE SUL TAB 15MG ER	384	19,769	8,574	\$1,382.63	\$10,605.21	MS Contin
May 2012	ORAMORPH SR TAB 15MG	1	1	1	\$0.00	\$1.00	MS Contin
May 2012	MORPHINE SUL TAB 30MG ER	432	26,873	11,519	\$1,518.44	\$19,527.70	MS Contin
May 2012	MORPHINE SUL TAB 60MG ER	215	14,772	5,975	\$709.24	\$11,741.31	MS Contin
May 2012	MORPHINE SUL TAB 100MG ER	136	9,210	3,582	\$514.08	\$22,233.96	MS Contin
May 2012	MORPHINE SUL TAB 200MG ER	10	539	240	\$42.84	\$2,639.28	MS Contin
May 2012	NUCYNTA ER TAB 50MG	1	30	30	\$4.76	\$79.12	Nucynta ER
May 2012	NUCYNTA ER TAB 100MG	4	210	105	\$19.04	\$980.80	Nucynta ER
May 2012	NUCYNTA ER TAB 150MG	3	180	90	\$14.28	\$1,075.50	Nucynta ER

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
May 2012	NUCYNTA ER TAB 200MG	2	120	60	\$9.52	\$910.38	Nucynta ER
May 2012	OPANA ER TAB 5MG	2	120	60	\$9.52	\$240.64	Opana ER
May 2012	OPANA ER TAB 10MG	1	60	30	\$4.76	\$226.65	Opana ER
May 2012	OPANA ER TAB 20MG	2	120	60	\$9.52	\$796.62	Opana ER
May 2012	OPANA ER TAB 30MG	2	120	60	\$4.76	\$574.51	Opana ER
May 2012	OPANA ER TAB 40MG	6	390	180	\$28.56	\$4,834.40	Opana ER
May 2012	OPANA ER TAB 10MG	5	300	150	\$9.52	\$463.20	Opana ER
May 2012	OPANA ER TAB 20MG	10	720	300	\$33.32	\$3,186.88	Opana ER
May 2012	OPANA ER TAB 30MG	9	600	270	\$38.08	\$4,856.20	Opana ER
May 2012	OPANA ER TAB 40MG	25	1,920	735	\$66.64	\$11,193.33	Opana ER
May 2012	OXYCONTIN TAB 10MG CR	26	927	417	\$71.40	\$1,201.93	Oxycontin
May 2012	OXYCONTIN TAB 15MG CR	5	300	150	\$9.52	\$389.84	Oxycontin
May 2012	OXYCONTIN TAB 20MG CR	72	3,028	1,375	\$261.20	\$7,673.86	Oxycontin
May 2012	OXYCONTIN TAB 30MG CR	12	673	321	\$28.56	\$1,795.71	Oxycontin
May 2012	OXYCONTIN TAB 40MG CR	68	4,836	1,866	\$247.52	\$25,773.84	Oxycontin
May 2012	OXYCONTIN TAB 60MG CR	25	1,907	711	\$71.40	\$10,506.19	Oxycontin
May 2012	OXYCONTIN TAB 80MG CR	73	6,185	2,128	\$285.60	\$64,980.92	Oxycontin
May 2012	TRAMADOL HCL TAB 100MG ER	6	390	180	\$19.04	\$928.48	Tramadol HCL
May 2012	TRAMADOL HCL TAB 200MG ER	4	120	120	\$19.04	\$564.68	Tramadol HCL
May 2012	TRAMADOL HCL TAB 300MG ER	3	90	90	\$14.28	\$694.29	Tramadol HCL
June 2012	AVINZA CAP 30MG	1	30	30	\$4.76	\$132.20	Avinza
June 2012	AVINZA CAP 60MG	1	30	30	\$0.00	\$3.30	Avinza
June 2012	DURAGESIC DIS 12MCG/HR	3	21	61	\$9.52	\$366.39	Fentanyl Patches
June 2012	FENTANYL DIS 12MCG/HR	12	88	252	\$19.04	\$482.75	Fentanyl Patches
June 2012	DURAGESIC DIS 25MCG/HR	12	125	325	\$52.36	\$2,105.26	Fentanyl Patches
June 2012	FENTANYL DIS 25MCG/HR	50	427	1,118	\$114.24	\$1,577.26	Fentanyl Patches
June 2012	DURAGESIC DIS 50MCG/HR	31	312	860	\$147.56	\$8,394.50	Fentanyl Patches
June 2012	FENTANYL DIS 50MCG/HR	38	312	846	\$47.60	\$394.41	Fentanyl Patches
June 2012	DURAGESIC DIS 75MCG/HR	10	120	298	\$47.60	\$6,565.70	Fentanyl Patches
June 2012	FENTANYL DIS 75MCG/HR	34	324	875	\$76.16	\$2,395.01	Fentanyl Patches
June 2012	DURAGESIC DIS 100MCG/H	18	149	395	\$85.68	\$9,078.20	Fentanyl Patches
June 2012	FENTANYL DIS 100MCG/H	50	353	909	\$76.16	\$2,529.58	Fentanyl Patches
June 2012	KADIAN CAP 10MG CR	8	270	165	\$38.08	\$1,254.68	Kadian
June 2012	KADIAN CAP 20MG CR	6	360	180	\$28.56	\$1,820.58	Kadian
June 2012	MORPHINE SUL CAP 20MG ER	1	60	30	\$4.76	\$224.99	Kadian
June 2012	KADIAN CAP 30MG CR	13	640	360	\$61.88	\$3,526.85	Kadian
June 2012	MORPHINE SUL CAP 30MG ER	3	210	90	\$9.52	\$529.29	Kadian
June 2012	KADIAN CAP 50MG CR	8	390	210	\$33.32	\$2,808.39	Kadian
June 2012	MORPHINE SUL CAP 50MG ER	2	120	60	\$9.52	\$940.10	Kadian
June 2012	KADIAN CAP 60MG CR	12	690	360	\$52.36	\$6,705.87	Kadian
June 2012	MORPHINE SUL CAP 60MG ER	2	120	60	\$4.76	\$489.09	Kadian
June 2012	KADIAN CAP 80MG CR	7	420	195	\$33.32	\$6,091.89	Kadian
June 2012	KADIAN CAP 100MG CR	13	735	382	\$52.36	\$10,978.10	Kadian
June 2012	MORPHINE SUL CAP 100MG ER	1	30	30	\$0.00	\$1.10	Kadian
June 2012	KADIAN CAP 200MG CR	3	120	60	\$14.28	\$4,401.14	Kadian
June 2012	METHADONE CON 10MG/ML	5	206	82	\$23.80	\$42.14	Methadone Concentrate
June 2012	METHADONE SOL 5MG/5ML	5	326	76	\$23.80	\$49.30	Methadone Solution
June 2012	METHADONE TAB 5MG	50	3,232	898	\$182.17	\$358.26	Methadone Tab
June 2012	METHADONE TAB 10MG	462	81,502	12,562	\$1,711.32	\$9,309.72	Methadone Tab
June 2012	MORPHINE SUL TAB 15MG ER	358	19,214	8,293	\$1,344.90	\$10,196.29	MS Contin

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
June 2012	ORAMORPH SR TAB 15MG	3	10	3	\$0.00	\$6.42	MS Contin
June 2012	MORPHINE SUL TAB 30MG ER	409	25,324	10,682	\$1,524.85	\$19,327.58	MS Contin
June 2012	MORPHINE SUL TAB 60MG ER	222	14,251	5,893	\$694.96	\$11,074.17	MS Contin
June 2012	MORPHINE SUL TAB 100MG ER	112	7,534	2,928	\$395.08	\$17,819.60	MS Contin
June 2012	MORPHINE SUL TAB 200MG ER	13	700	278	\$57.12	\$3,147.07	MS Contin
June 2012	NUCYNTA ER TAB 100MG	5	254	134	\$23.80	\$1,187.08	Nucynta ER
June 2012	NUCYNTA ER TAB 150MG	3	180	90	\$14.28	\$1,075.50	Nucynta ER
June 2012	NUCYNTA ER TAB 200MG	2	120	60	\$9.52	\$910.38	Nucynta ER
June 2012	OPANA ER TAB 5MG	1	60	30	\$0.00	\$3.30	Opana ER
June 2012	OPANA ER TAB 10MG	1	60	30	\$4.76	\$226.65	Opana ER
June 2012	OPANA ER TAB 20MG	2	120	60	\$9.52	\$796.62	Opana ER
June 2012	OPANA ER TAB 30MG	2	120	60	\$9.52	\$1,142.42	Opana ER
June 2012	OPANA ER TAB 40MG	1	60	30	\$4.76	\$744.12	Opana ER
June 2012	OPANA ER TAB 10MG	4	210	120	\$4.76	\$236.55	Opana ER
June 2012	OPANA ER TAB 20MG	14	898	404	\$57.12	\$5,005.31	Opana ER
June 2012	OPANA ER TAB 30MG	9	570	270	\$38.08	\$4,856.20	Opana ER
June 2012	OPANA ER TAB 40MG	22	1,378	644	\$85.68	\$13,752.40	Opana ER
June 2012	OXYCONTIN TAB 10MG CR	22	715	297	\$61.88	\$953.16	Oxycontin
June 2012	OXYCONTIN TAB 15MG CR	4	240	120	\$9.52	\$386.54	Oxycontin
June 2012	OXYCONTIN TAB 20MG CR	52	2,843	1,197	\$180.88	\$7,020.99	Oxycontin
June 2012	OXYCONTIN TAB 30MG CR	15	1,080	435	\$42.84	\$3,414.26	Oxycontin
June 2012	OXYCONTIN TAB 40MG CR	67	4,363	1,734	\$233.24	\$22,004.06	Oxycontin
June 2012	OXYCONTIN TAB 60MG CR	12	986	359	\$38.08	\$5,271.15	Oxycontin
June 2012	OXYCONTIN TAB 80MG CR	63	5,239	1,822	\$266.56	\$57,737.93	Oxycontin
June 2012	TRAMADOL HCL TAB 100MG ER	6	450	165	\$28.56	\$981.28	Tramadol HCL
June 2012	TRAMADOL HCL TAB 200MG ER	4	107	107	\$19.04	\$505.58	Tramadol HCL
June 2012	TRAMADOL HCL TAB 300MG ER	1	30	30	\$4.76	\$234.65	Tramadol HCL
July 2012	AVINZA CAP 30MG	1	30	30	\$4.76	\$143.67	Avinza
July 2012	AVINZA CAP 60MG	1	30	30	\$0.00	\$3.30	Avinza
July 2012	DURAGESIC DIS 12MCG/HR	1	10	30	\$4.76	\$205.68	Fentanyl Patches
July 2012	FENTANYL DIS 12MCG/HR	7	37	92	\$4.76	\$147.22	Fentanyl Patches
July 2012	DURAGESIC DIS 25MCG/HR	17	120	327	\$66.64	\$1,617.67	Fentanyl Patches
July 2012	FENTANYL DIS 25MCG/HR	40	343	965	\$99.96	\$1,234.17	Fentanyl Patches
July 2012	DURAGESIC DIS 50MCG/HR	46	333	940	\$218.96	\$10,234.58	Fentanyl Patches
July 2012	FENTANYL DIS 50MCG/HR	33	342	906	\$42.84	\$1,092.07	Fentanyl Patches
July 2012	DURAGESIC DIS 75MCG/HR	12	140	360	\$57.12	\$6,719.97	Fentanyl Patches
July 2012	FENTANYL DIS 75MCG/HR	33	296	813	\$90.44	\$2,374.45	Fentanyl Patches
July 2012	DURAGESIC DIS 100MCG/H	18	185	471	\$85.68	\$12,077.07	Fentanyl Patches
July 2012	FENTANYL DIS 100MCG/H	30	245	639	\$71.40	\$2,530.86	Fentanyl Patches
July 2012	KADIAN CAP 10MG CR	7	150	75	\$33.32	\$709.21	Kadian
July 2012	KADIAN CAP 20MG CR	4	240	120	\$19.04	\$1,213.72	Kadian
July 2012	MORPHINE SUL CAP 20MG ER	3	120	90	\$9.52	\$347.48	Kadian
July 2012	KADIAN CAP 30MG CR	15	726	408	\$71.40	\$4,001.97	Kadian
July 2012	MORPHINE SUL CAP 30MG ER	2	150	60	\$4.76	\$284.30	Kadian
July 2012	KADIAN CAP 50MG CR	10	446	238	\$34.61	\$2,451.13	Kadian
July 2012	MORPHINE SUL CAP 50MG ER	4	240	120	\$19.04	\$1,740.08	Kadian
July 2012	KADIAN CAP 60MG CR	11	585	315	\$52.36	\$6,376.78	Kadian
July 2012	MORPHINE SUL CAP 60MG ER	1	60	30	\$0.00	\$1.10	Kadian
July 2012	KADIAN CAP 80MG CR	5	300	135	\$23.80	\$4,338.00	Kadian
July 2012	MORPHINE SUL CAP 80MG ER	1	60	30	\$4.76	\$746.64	Kadian

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
July 2012	KADIAN CAP 100MG CR	10	570	300	\$42.84	\$8,824.30	Kadian
July 2012	MORPHINE SUL CAP 100MG ER	1	30	30	\$0.00	\$1.10	Kadian
July 2012	KADIAN CAP 200MG CR	3	120	60	\$14.28	\$4,401.14	Kadian
July 2012	METHADOSE CON 10MG/ML	3	143	55	\$14.28	\$27.00	Methadone Concentrate
July 2012	METHADONE SOL 5MG/5ML	1	1	7	\$4.76	\$4.84	Methadone Solution
July 2012	METHADONE TAB 5MG	45	2,904	808	\$188.65	\$367.41	Methadone Tab
July 2012	METHADONE TAB 10MG	487	83,485	12,849	\$1,858.89	\$9,761.67	Methadone Tab
July 2012	METHADOSE TAB 40MG	3	4	3	\$0.00	\$1.07	Methadone Tab
July 2012	MORPHINE SUL TAB 15MG ER	369	20,623	8,688	\$1,407.39	\$10,172.61	MS Contin
July 2012	ORAMORPH SR TAB 15MG	2	2	2	\$0.00	\$1.20	MS Contin
July 2012	MORPHINE SUL TAB 30MG ER	397	25,091	10,585	\$1,585.08	\$20,317.08	MS Contin
July 2012	MS CONTIN TAB 30MG CR	1	30	30	\$0.00	\$3.30	MS Contin
July 2012	MORPHINE SUL TAB 60MG ER	215	14,040	5,846	\$752.08	\$11,242.79	MS Contin
July 2012	MORPHINE SUL TAB 100MG ER	112	7,882	3,113	\$404.60	\$18,676.96	MS Contin
July 2012	MORPHINE SUL TAB 200MG ER	8	594	238	\$33.32	\$3,157.63	MS Contin
July 2012	NUCYNTA ER TAB 50MG	1	60	30	\$4.76	\$160.91	Nucynta ER
July 2012	NUCYNTA ER TAB 100MG	2	120	60	\$4.76	\$296.59	Nucynta ER
July 2012	NUCYNTA ER TAB 150MG	4	240	120	\$19.04	\$1,469.36	Nucynta ER
July 2012	NUCYNTA ER TAB 200MG	3	180	90	\$14.28	\$1,433.13	Nucynta ER
July 2012	OPANA ER TAB 5MG	1	60	30	\$4.76	\$120.32	Opana ER
July 2012	OPANA ER TAB 20MG	2	120	60	\$9.52	\$796.62	Opana ER
July 2012	OPANA ER TAB 10MG	8	540	240	\$28.56	\$1,588.40	Opana ER
July 2012	OPANA ER TAB 20MG	12	780	360	\$42.84	\$3,988.23	Opana ER
July 2012	OPANA ER TAB 30MG	10	638	304	\$47.60	\$6,070.85	Opana ER
July 2012	OPANA ER TAB 40MG	21	1,254	612	\$85.68	\$13,206.89	Opana ER
July 2012	OXYCONTIN TAB 10MG CR	21	729	312	\$47.60	\$828.39	Oxycontin
July 2012	OXYCONTIN TAB 15MG CR	9	485	237	\$28.56	\$971.13	Oxycontin
July 2012	OXYCONTIN TAB 20MG CR	35	2,018	851	\$133.28	\$6,298.86	Oxycontin
July 2012	OXYCONTIN TAB 30MG CR	13	870	390	\$42.84	\$3,573.09	Oxycontin
July 2012	OXYCONTIN TAB 40MG CR	48	3,285	1,379	\$166.60	\$16,375.65	Oxycontin
July 2012	OXYCONTIN TAB 60MG CR	17	1,532	511	\$66.64	\$8,656.66	Oxycontin
July 2012	OXYCONTIN TAB 80MG CR	60	4,937	1,722	\$257.04	\$56,207.38	Oxycontin
July 2012	TRAMADOL HCL TAB 100MG ER	6	450	180	\$28.56	\$1,056.35	Tramadol HCL
July 2012	TRAMADOL HCL TAB 200MG ER	3	120	90	\$14.28	\$559.93	Tramadol HCL
July 2012	TRAMADOL HCL TAB 300MG ER	3	120	90	\$14.28	\$990.14	Tramadol HCL
August 2012	AVINZA CAP 60MG	1	30	30	\$0.00	\$3.30	Avinza
August 2012	DURAGESIC DIS 12MCG/HR	1	5	15	\$4.76	\$72.69	Fentanyl Patches
August 2012	FENTANYL DIS 12MCG/HR	9	44	132	\$0.00	\$9.90	Fentanyl Patches
August 2012	DURAGESIC DIS 25MCG/HR	26	195	552	\$114.24	\$3,223.75	Fentanyl Patches
August 2012	FENTANYL DIS 25MCG/HR	42	406	1,109	\$76.16	\$966.16	Fentanyl Patches
August 2012	DURAGESIC DIS 50MCG/HR	33	274	773	\$157.08	\$8,153.85	Fentanyl Patches
August 2012	FENTANYL DIS 50MCG/HR	35	339	906	\$47.60	\$1,079.70	Fentanyl Patches
August 2012	DURAGESIC DIS 75MCG/HR	16	180	480	\$76.16	\$9,638.71	Fentanyl Patches
August 2012	FENTANYL DIS 75MCG/HR	30	251	674	\$57.12	\$1,350.76	Fentanyl Patches
August 2012	DURAGESIC DIS 100MCG/H	15	149	372	\$71.40	\$10,114.88	Fentanyl Patches
August 2012	FENTANYL DIS 100MCG/H	24	208	529	\$57.12	\$2,101.01	Fentanyl Patches
August 2012	KADIAN CAP 10MG CR	6	180	90	\$28.56	\$839.62	Kadian
August 2012	KADIAN CAP 20MG CR	7	390	210	\$28.56	\$1,823.88	Kadian
August 2012	MORPHINE SUL CAP 20MG ER	1	60	30	\$4.76	\$220.99	Kadian
August 2012	KADIAN CAP 30MG CR	10	540	300	\$47.60	\$2,971.16	Kadian

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
August 2012	MORPHINE SUL CAP 30MG ER	3	180	90	\$9.52	\$567.50	Kadian
August 2012	KADIAN CAP 50MG CR	10	468	234	\$38.94	\$3,087.11	Kadian
August 2012	MORPHINE SUL CAP 50MG ER	4	240	120	\$14.28	\$1,325.33	Kadian
August 2012	KADIAN CAP 60MG CR	10	550	290	\$47.60	\$6,003.00	Kadian
August 2012	MORPHINE SUL CAP 60MG ER	1	60	30	\$0.00	\$1.10	Kadian
August 2012	KADIAN CAP 80MG CR	8	448	199	\$38.08	\$6,473.86	Kadian
August 2012	MORPHINE SUL CAP 80MG ER	2	120	60	\$9.52	\$1,493.28	Kadian
August 2012	KADIAN CAP 100MG CR	13	720	390	\$57.12	\$11,780.07	Kadian
August 2012	MORPHINE SUL CAP 100MG ER	1	30	30	\$0.00	\$1.10	Kadian
August 2012	KADIAN CAP 200MG CR	2	120	60	\$9.52	\$4,396.38	Kadian
August 2012	METHADONE CON 10MG/ML	2	26	10	\$9.52	\$11.84	Methadone Concentrate
August 2012	METHADONE SOL 5MG/5ML	1	11	10	\$4.76	\$5.47	Methadone Solution
August 2012	METHADONE SOL 10MG/5ML	1	11	30	\$4.76	\$6.37	Methadone Solution
August 2012	METHADONE TAB 5MG	47	3,175	982	\$192.12	\$374.26	Methadone Tab
August 2012	METHADONE TAB 10MG	476	83,390	12,582	\$1,817.14	\$9,969.07	Methadone Tab
August 2012	METHADONE TAB 40MG	1	1	1	\$0.00	\$0.27	Methadone Tab
August 2012	MORPHINE SUL TAB 15MG ER	393	19,978	8,914	\$1,524.11	\$10,845.78	MS Contin
August 2012	MORPHINE SUL TAB 30MG ER	459	28,001	11,794	\$1,759.74	\$22,420.84	MS Contin
August 2012	MS CONTIN TAB 30MG CR	1	30	30	\$4.76	\$32.20	MS Contin
August 2012	MORPHINE SUL TAB 60MG ER	205	14,042	5,767	\$705.58	\$11,265.76	MS Contin
August 2012	MORPHINE SUL TAB 100MG ER	110	7,509	2,987	\$399.84	\$17,094.88	MS Contin
August 2012	MORPHINE SUL TAB 200MG ER	6	420	180	\$23.80	\$1,918.88	MS Contin
August 2012	NUCYN TA ER TAB 50MG	1	60	30	\$4.76	\$160.91	Nucynta ER
August 2012	NUCYN TA ER TAB 100MG	7	420	211	\$33.32	\$2,053.03	Nucynta ER
August 2012	NUCYN TA ER TAB 150MG	1	60	30	\$4.76	\$376.18	Nucynta ER
August 2012	NUCYN TA ER TAB 200MG	3	180	90	\$14.28	\$1,433.13	Nucynta ER
August 2012	OPANA ER TAB 10MG	1	28	14	\$4.76	\$24.88	Opana ER
August 2012	OPANA ER TAB 20MG	1	60	30	\$4.76	\$398.31	Opana ER
August 2012	OPANA ER TAB 40MG	1	60	30	\$4.76	\$744.12	Opana ER
August 2012	OPANA ER TAB 5MG	1	60	30	\$0.00	\$3.30	Opana ER
August 2012	OPANA ER TAB 10MG	5	330	150	\$9.52	\$574.15	Opana ER
August 2012	OPANA ER TAB 20MG	17	990	495	\$61.88	\$4,679.71	Opana ER
August 2012	OPANA ER TAB 30MG	10	750	300	\$42.84	\$6,277.07	Opana ER
August 2012	OPANA ER TAB 40MG	24	1,470	720	\$104.72	\$16,746.92	Opana ER
August 2012	OXYCONTIN TAB 10MG CR	16	810	371	\$38.08	\$1,184.39	Oxycontin
August 2012	OXYCONTIN TAB 15MG CR	4	190	95	\$9.52	\$205.27	Oxycontin
August 2012	OXYCONTIN TAB 20MG CR	38	2,462	1,021	\$133.28	\$7,034.70	Oxycontin
August 2012	OXYCONTIN TAB 30MG CR	18	1,280	536	\$66.64	\$5,219.06	Oxycontin
August 2012	OXYCONTIN TAB 40MG CR	45	2,979	1,293	\$147.56	\$15,170.19	Oxycontin
August 2012	OXYCONTIN TAB 60MG CR	12	962	361	\$47.60	\$6,792.44	Oxycontin
August 2012	OXYCONTIN TAB 80MG CR	60	5,154	1,789	\$276.08	\$62,059.04	Oxycontin
August 2012	TRAMADOL HCL TAB 100MG ER	6	450	180	\$28.56	\$981.50	Tramadol HCL
August 2012	TRAMADOL HCL TAB 200MG ER	2	60	60	\$9.52	\$282.34	Tramadol HCL
August 2012	TRAMADOL HCL TAB 300MG ER	1	30	30	\$4.76	\$234.65	Tramadol HCL
August 2012	TRAMADOL HCL TAB 300MG ER	2	60	60	\$9.52	\$464.40	Tramadol HCL
September 2012	AVINZA CAP 30MG	1	30	30	\$4.76	\$143.67	Avinza
September 2012	AVINZA CAP 60MG	1	30	30	\$0.00	\$3.30	Avinza
September 2012	DURAGESIC DIS 12MCG/HR	1	5	15	\$4.76	\$105.22	Fentanyl Patches
September 2012	FENTANYL DIS 12MCG/HR	2	12	36	\$0.00	\$2.20	Fentanyl Patches
September 2012	DURAGESIC DIS 25MCG/HR	28	173	508	\$128.52	\$3,395.27	Fentanyl Patches

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
September 2012	FENTANYL DIS 25MCG/HR	23	226	646	\$28.56	\$483.70	Fentanyl Patches
September 2012	DURAGESIC DIS 50MCG/HR	37	315	900	\$176.12	\$11,516.35	Fentanyl Patches
September 2012	FENTANYL DIS 50MCG/HR	26	233	598	\$33.32	\$993.43	Fentanyl Patches
September 2012	DURAGESIC DIS 75MCG/HR	22	196	528	\$104.72	\$11,235.00	Fentanyl Patches
September 2012	FENTANYL DIS 75MCG/HR	22	219	550	\$38.08	\$838.87	Fentanyl Patches
September 2012	DURAGESIC DIS 100MCG/H	22	165	419	\$104.72	\$12,901.37	Fentanyl Patches
September 2012	FENTANYL DIS 100MCG/H	17	144	386	\$42.84	\$1,360.03	Fentanyl Patches
September 2012	KADIAN CAP 10MG CR	6	240	120	\$28.56	\$1,109.96	Kadian
September 2012	KADIAN CAP 20MG CR	7	420	210	\$28.56	\$1,741.44	Kadian
September 2012	MORPHINE SUL CAP 20MG ER	3	120	90	\$9.52	\$347.48	Kadian
September 2012	KADIAN CAP 30MG CR	12	580	350	\$57.12	\$3,197.25	Kadian
September 2012	MORPHINE SUL CAP 30MG ER	4	240	120	\$14.28	\$807.49	Kadian
September 2012	KADIAN CAP 50MG CR	13	510	251	\$44.80	\$2,751.36	Kadian
September 2012	MORPHINE SUL CAP 50MG ER	2	120	60	\$9.52	\$854.18	Kadian
September 2012	KADIAN CAP 60MG CR	8	420	225	\$38.08	\$4,585.84	Kadian
September 2012	MORPHINE SUL CAP 60MG ER	2	120	60	\$0.00	\$2.20	Kadian
September 2012	KADIAN CAP 80MG CR	8	450	225	\$38.08	\$6,502.71	Kadian
September 2012	MORPHINE SUL CAP 80MG ER	1	60	30	\$4.76	\$746.64	Kadian
September 2012	KADIAN CAP 100MG CR	12	720	360	\$52.36	\$11,229.08	Kadian
September 2012	KADIAN CAP 200MG CR	2	120	60	\$9.52	\$4,396.38	Kadian
September 2012	METHADOSE CON 10MG/ML	2	78	30	\$9.52	\$16.46	Methadone Concentrate
September 2012	METHADONE SOL 5MG/5ML	5	452	100	\$23.80	\$57.18	Methadone Solution
September 2012	METHADONE SOL 10MG/5ML	2	185	31	\$4.76	\$30.39	Methadone Solution
September 2012	METHADONE TAB 5MG	39	2,665	852	\$148.85	\$303.13	Methadone Tab
September 2012	METHADONE TAB 10MG	429	74,835	11,313	\$1,655.23	\$8,966.67	Methadone Tab
September 2012	MORPHINE SUL TAB 15MG ER	366	19,200	8,500	\$1,448.86	\$10,439.28	MS Contin
September 2012	MS CONTIN TAB 15MG CR	2	2	2	\$0.00	\$1.20	MS Contin
September 2012	ORAMORPH SR TAB 15MG	1	1	1	\$0.00	\$0.60	MS Contin
September 2012	MORPHINE SUL TAB 30MG ER	384	24,015	9,850	\$1,483.52	\$18,768.05	MS Contin
September 2012	MORPHINE SUL TAB 60MG ER	188	12,274	4,986	\$647.36	\$10,086.43	MS Contin
September 2012	MORPHINE SUL TAB 100MG ER	94	6,569	2,635	\$347.48	\$15,607.49	MS Contin
September 2012	MORPHINE SUL TAB 200MG ER	7	540	210	\$28.56	\$2,346.91	MS Contin
September 2012	NUCYNTA ER TAB 50MG	2	150	45	\$9.52	\$399.90	Nucynta ER
September 2012	NUCYNTA ER TAB 100MG	3	180	90	\$14.28	\$879.87	Nucynta ER
September 2012	NUCYNTA ER TAB 150MG	6	360	180	\$28.56	\$2,257.08	Nucynta ER
September 2012	NUCYNTA ER TAB 200MG	2	120	60	\$9.52	\$955.42	Nucynta ER
September 2012	OXYMORPHONE TAB 15MG ER	3	150	75	\$9.52	\$386.83	Oxymorphone
September 2012	OPANA ER TAB 20MG	1	60	30	\$0.00	\$3.30	Opana ER
September 2012	OPANA ER TAB 40MG	1	60	30	\$4.76	\$744.12	Opana ER
September 2012	OPANA ER TAB 5MG	1	60	30	\$0.00	\$3.30	Opana ER
September 2012	OPANA ER TAB 10MG	4	270	120	\$4.76	\$347.50	Opana ER
September 2012	OPANA ER TAB 20MG	16	983	480	\$61.88	\$5,335.80	Opana ER
September 2012	OPANA ER TAB 30MG	9	630	270	\$38.08	\$5,422.64	Opana ER
September 2012	OPANA ER TAB 40MG	13	790	395	\$52.36	\$7,597.78	Opana ER
September 2012	OXYCONTIN TAB 10MG CR	16	698	299	\$42.84	\$1,120.13	Oxycontin
September 2012	OXYCONTIN TAB 15MG CR	3	180	90	\$0.00	\$9.90	Oxycontin
September 2012	OXYCONTIN TAB 20MG CR	38	2,225	955	\$142.80	\$6,678.48	Oxycontin
September 2012	OXYCONTIN TAB 30MG CR	14	908	389	\$52.36	\$3,786.94	Oxycontin
September 2012	OXYCONTIN TAB 40MG CR	36	2,321	1,056	\$138.04	\$13,045.07	Oxycontin
September 2012	OXYCONTIN TAB 60MG CR	9	632	271	\$38.08	\$5,250.49	Oxycontin

Month Claim Submitted	Drug Label Name	Claim Count	Quantity Dispensed	Days Supply	Dispensing Fee	Total Amount Paid	Group
September 2012	OXYCONTIN TAB 80MG CR	58	4,768	1,656	\$266.56	\$57,138.08	Oxycontin
September 2012	TRAMADOL HCL TAB 100MG ER	3	240	90	\$14.28	\$389.88	Tramadol HCL
September 2012	TRAMADOL HCL TAB 200MG ER	2	60	60	\$9.52	\$282.34	Tramadol HCL
September 2012	TRAMADOL HCL TAB 300MG ER	4	150	120	\$19.04	\$1,224.79	Tramadol HCL

Therapeutic Class Overview Long-acting Opioids

Therapeutic Class

- Overview/Summary:** Pain is one of the most common and debilitating patient complaints, with persistent pain having the potential to lead to functional impairment, disability, psychological distress and sleep deprivation. Pain can be categorized as being either nociceptive or neuropathic, and the treatments for each are specific. Nociceptive pain is caused by damage to tissues and can further be divided into somatic (pain arising from injury to body tissues) and visceral pain (pain arising from the internal organs). Visceral pain is often described as poorly localized, deep, dull, and cramping. In contrast, neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system.¹ Pharmacologic therapy should not be the sole focus of pain treatment; however, it is the most widely utilized option to manage chronic pain. Major pharmacologic categories used in the management of pain include nonopioid analgesics, tramadol, opioid analgesics, α -2 adrenergic agonists, antidepressants, anticonvulsants, muscle relaxants, N-methyl-D-aspartate receptor antagonists, and topical analgesics. Combining pharmacologic therapies may result in improved analgesia, and because lower doses of each agent can be used, patients may experience fewer treatment-emergent adverse events. Response to pharmacologic therapies will vary between individual patients, and currently no one approach has been demonstrated to be appropriate for all patients. Treatment decisions are largely based on the type of pain (e.g., neuropathic, nociceptive), comorbidities, concurrent medications, pharmacokinetic/pharmacodynamic properties of the agent and anticipated adverse events.²

As a class, opioid analgesics encompass a group of naturally occurring, semisynthetic, and synthetic drugs that stimulate opiate receptors and effectively relieve pain without producing loss of consciousness.³⁻¹⁹ These agents primarily produce intense analgesia via their agonist actions at mu receptors, which are found in large numbers within the central nervous system. The binding of these agents to mu receptors produces a variety of other effects including bradycardia, sedation, euphoria, physical dependence, and respiratory depression. Key safety concerns associated with the opioid analgesics include respiratory depression, and to a lesser degree, circulatory depression.^{2,20} The long-acting opioids are primarily utilized in the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.³ Long-acting opioids are available in a variety of different dosage forms, and currently several agents are available generically.³

Oxycontin[®] (oxycodone extended-release) has received increased attention regarding overuse, abuse, and diversion, but oxycodone itself does not appear to have a greater dependence or abuse liability compared to the other available opioids.²¹ The Food and Drug Administration (FDA) approved a new Oxycontin[®] formulation in April of 2010 that was designed to discourage misuse and abuse. The reformulated Oxycontin[®] is intended to prevent the medication from being cut, broken, chewed, crushed, or dissolved to release more medication. The FDA states that the new formulation may result in less risk of overdose due to tampering, and will likely result in less abuse by snorting or injection, but the agent can still be abused or misused by ingesting larger than recommended doses. The manufacturer is required to conduct a postmarketing study evaluating the extent to which the new formulation reduces abuse and misuse.²² Similarly, a new, crush-resistant formulation of Opana ER[®] (oxymorphone extended-release) was approved in December 2011; however, the manufacturer notes that it has not been established that the new formulation is less subject to misuse, abuse, diversion, overdose or addiction.²³

Table 1. Current Medications Available in Therapeutic Class⁴⁻¹⁹

Generic (Trade Name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
Single-Entity Agents			
Buprenorphine	The management of moderate to severe	Transdermal	-

Generic (Trade Name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
(Butrans [®])	chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time	system: 5 µg/hour 10 µg/hour 20 µg/hour	
Fentanyl (Duragesic ^{®*})	The management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids	Transdermal system: † 12 µg/hour 25 µg/hour 50 µg/hour 75 µg/hour 100 µg/hour	a
Hydromorphone (Exalgo [®])	The management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time	Extended release tablets: † 8 mg 12 mg 16 mg	-
Methadone (Dolophine ^{®*} , Methadose ^{®*})	Treatment of moderate to severe pain not responsive to non-narcotic analgesics, for detoxification treatment of opioid addiction (heroin or other morphine-like drugs) and for maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services	Concentrate (sugar-free available): 10 mg/mL Dispersible tablet: 40 mg Solution: 5 mg/5 mL 10 mg/5 mL Tablet: 5 mg 10 mg	a
Morphine sulfate (Avinza [®] , Kadian ^{®*} , MS Contin ^{®*} , Oramorph SR [®])	For the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (Avinza [®]), for the relief of moderate to severe pain requiring continuous, around the clock opioid therapy for an extended period of time (Kadian [®] and MS Contin [®]) and for the relief of pain in patients who require opioid analgesics for more than a few days (Oramorph SR [®])	Extended release capsules: 10 mg [§] 20 mg [§] 30 mg [§] 45 mg 50 mg [§] 60 mg ^{†,} 75 mg 80 mg [§] 90 mg ^{†,} 100 mg ^{†,§} 120 mg ^{†,} 200 mg ^{†,§} Extended release tablets: 15 mg 30 mg 60 mg 100 mg [§]	a

Generic (Trade Name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
		200 mg [§] Tablet (Oramorph SR [®]) 15 mg 30 mg 60 mg 100 mg	
Oxycodone (Oxycontin ^{®*})	For the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time	Extended release tablet: 10 mg 15 mg [#] 20 mg 30 mg [#] 40 mg 60 mg ^{†,#} 80 mg [†]	a [†]
Oxymorphone (Opana [®] ER)	For the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time	Extended release tablet: 5 mg 7.5 mg 10 mg 15 mg 20 mg 30 mg 40 mg	-
Tapentadol (Nucynta ER [®])	For the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time and treatment of neuropathic pain associated with diabetic peripheral neuropathy in adults	Extended release tablet: 50 mg 100 mg 150 mg 200 mg 250 mg	-
Combination Products			
Morphine sulfate/ naltrexone	For the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time	Extended release capsule: 20 mg/0.8 mg 30 mg/1.2 mg 50 mg/2 mg 60 mg/2.4 mg 80 mg/3.2 mg [†] 100 mg/4 mg [†]	-

*Generic is available in at least one dosage form or strength.

†Generic availability is sporadic and does not include all strengths.

‡For use in opioid-tolerant patients only.

§Kadian[®] only.

||Avinza[®] only.

¶Avinza[®] 60 mg extended-release capsules are for use in opioid-tolerant patients only.

#Oxycontin[®] only.

Evidence-based Medicine

- In one trial, treatment with the buprenorphine transdermal system resulted in significant improvement in the average pain score over the last 24 hours at week 12 compared to treatment with buprenorphine 5 µg/hour ($P < 0.001$ for both). In a second trial, treatment with either 10 or 20 µg/hour

of buprenorphine transdermal system resulted in a treatment difference in favor of buprenorphine (95% confidence interval [CI], -1.02 to -0.14; $P=0.01$) compared to placebo. Two other trials failed to show efficacy for buprenorphine transdermal system in patients with low back pain and osteoarthritis, respectively against oxycodone/acetaminophen and oxycodone immediate-release. In another trial, treatment with either buprenorphine transdermal system 20 $\mu\text{g}/\text{hour}$ or oxycodone immediate-release was compared to treatment with buprenorphine transdermal system 5 $\mu\text{g}/\text{hour}$ in patients with osteoarthritis. The decrease in the average pain score over the last 24 hours scores from baseline was greater in the buprenorphine transdermal system 20 $\mu\text{g}/\text{hour}$ and oxycodone immediate-release treatment groups as compared to the buprenorphine transdermal system 5 $\mu\text{g}/\text{hour}$ group, however the difference was not significant (P values not reported).^{4,24}

- The effectiveness of fentanyl in relieving pain appears to be similar to that of morphine sulfate sustained-release for the treatment of cancer and noncancer pain, and chronic lower back pain. Compared to morphine sulfate sustained-release, fentanyl transdermal systems appear to be associated with less constipation.²⁵⁻²⁷
- In one trial, hydromorphone extended-release demonstrated greater efficacy in the treatment of lower back pain with regard to reducing pain intensity ($P<0.001$) and pain scores ($P<0.01$) compared to placebo.²⁸ In a 2007 noninferiority analysis of a hydromorphone extended-release compared to oxycodone extended-release, it was demonstrated that the two agents provided similar pain relief in the management of osteoarthritic pain.²⁹
- Methadone has demonstrated a greater efficacy over placebo for the treatment of nonmalignant neuropathic pain and similar efficacy compared to slow-release morphine sulfate for the treatment of cancer pain.^{30,31}
- A trial comparing different long-acting formulations of morphine sulfate for the treatment of osteoarthritis pain demonstrated that both Avinza[®] (morphine sulfate extended-release) and MS Contin[®] (morphine sulfate controlled-release) significantly reduced pain from baseline ($P\leq 0.05$ for both). Both treatments also reduced overall arthritis pain intensity, and achieved comparable improvements in physical functioning and stiffness. Each of the treatments significantly improved certain sleep parameters compared to placebo.³² In another cross-over trial, morphine sulfate (MS Contin[®]) was compared to fentanyl transdermal systems and more patients preferred fentanyl transdermal systems ($P<0.001$), and reported on average, lower pain intensity scores than during the morphine sulfate phase ($P<0.001$).³³
- Morphine/naltrexone has demonstrated significantly better pain control compared to placebo in patients with osteoarthritis pain.³⁴
- Oxycodone controlled-release has demonstrated significantly greater efficacy compared to placebo for the treatment of neuropathic pain and chronic refractory neck pain.³⁵⁻³⁷ For the treatment of cancer pain, no significant differences were observed between oxycodone controlled-release and morphine sulfate controlled-release in reducing pain intensity. The average number of rescue doses used within a 24 hour period was significantly less with morphine sulfate controlled-release ($P=0.01$), and the incidence of nausea and sedation were similar between treatments.³⁸
- Oxymorphone extended-release has produced similar mean daily pain intensity scores compared to both morphine sulfate and oxycodone controlled-release for the treatment of chronic cancer pain.^{39,40} The average scheduled daily dose of study drug and average total daily dose decreased after patients crossed over to oxymorphone extended-release from morphine sulfate or oxycodone controlled-release. No significant changes were observed in visual analog pain scores, quality of life domains, or quality of sleep in any of the treatment groups.⁴⁰ In another trial, oxymorphone extended-release demonstrated greater efficacy for the relief of osteoarthritis pain compared to placebo.⁴¹
- In a 12-week active comparator and placebo-controlled trial, significant pain relief was achieved with tapentadol extended-release compared to placebo (least squares mean difference, - 0.7; 95% CI, - 1.04 to -0.33) at week 12. The average pain intensity rating at endpoint with oxycodone controlled-release was reduced significantly compared to placebo for the overall maintenance period (least squares mean difference vs placebo, -0.3), but was not significantly lower at week 12 (least squares mean, -0.3; P values not reported).⁴² In a, placebo-controlled and active comparator trial in adults with moderate to severe low back pain, improvements in average pain intensity scores occurred with tapentadol extended-release and oxycodone controlled-release relative to placebo ($P<0.001$).⁴³

Schwartz et al evaluated tapentadol extended-release among adults with painful diabetic peripheral neuropathy. The least squares mean change in average pain intensity at week 12 was 1.4 in the placebo group, indicating a worsening in pain intensity, and 0.0 in the tapentadol extended-release group, indicating no change in pain intensity, (least squares mean difference, -1.3; 95% CI, -1.70 to -0.92; $P < 0.001$).⁴⁴

- Methadone is the only long-acting narcotic that is Food and Drug Administration-approved for the management of opioid addiction; however, in one study slow-release morphine sulfate demonstrated noninferiority to methadone in terms of completion rate for the treatment of opioid addiction (51 vs 49%).⁴⁵

Key Points within the Medication Class

- According to Current Clinical Guidelines:
 - Patients with pain should be started on acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). If sufficient pain relief is not achieved, patients should be escalated to a “weak opioid” and then to a “strong opioid”, such as morphine.^{46,47}
 - Opioid selection, initial dosing, and titration should be individualized according to the patient’s health status, previous exposure to opioids, attainment of therapeutic goals, and predicted or observed harms. There is insufficient evidence to recommend short-acting vs long-acting opioids, or as needed vs around-the-clock dosing of opioids.⁴⁷
 - Patients with chronic persistent pain controlled by stable doses of short-acting opioids should be provided with round-the-clock extended-release or long-acting formulation opioids with provision of a ‘rescue dose’ to manage break-through or transient exacerbations of pain.⁴⁶
 - Opioids with rapid onset and short duration are preferred as rescue doses. The repeated need for rescue doses per day may indicate the necessity to adjust the baseline treatment.^{46,47}
 - In a patient who has not been exposed to opioids in the past, morphine is generally considered the standard starting drug of choice.⁴⁶
 - Pure agonists (such as codeine, fentanyl, oxycodone, and oxymorphone) are the most commonly used medications in the management of cancer pain. Opioid agonists with a short half-life are preferred and include fentanyl, hydromorphone, morphine, and oxycodone.⁴⁶
 - Meperidine, mixed agonist-antagonists, and placebos are not recommended for cancer patients. Meperidine is contraindicated for chronic pain especially in patients with impaired renal function or dehydration.⁴⁶
 - In patients who require relatively high doses of chronic opioid therapy, clinicians should evaluate for unique opioid-related adverse events, changes in health status, and adherence to the chronic opioid therapy treatment plan on an ongoing basis, and consider more frequent follow-up visits.^{46,47}
- Other Key Facts:
 - All of the long-acting opioids are classified as Schedule II controlled substances by the Food and Drug Administration (FDA), with the exception of buprenorphine transdermal systems which are a Schedule III controlled substance.⁴⁻¹⁹ Buprenorphine is a partial opiate agonist, and the transdermal system is the first and only seven-day transdermal opioid approved by the FDA.⁵
 - On July 9, 2012, the FDA approved a Risk Evaluation and Mitigation Strategy (REMS) for all long-acting opioids. The program will require companies who manufacture long-acting opioids to make training regarding proper prescribing practices available for health care professionals who prescribe these agents, as well as distribute educational materials to both prescribers and patients on the safe use of these agents.⁴⁸
 - The new REMS program is part of the national prescription drug abuse plan announced by the Obama Administration in 2011 to combat prescription drug misuse and abuse.⁴⁸

References

1. Smith HS. Definition and pathogenesis of chronic pain. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2011 [cited 2012 Oct]. Available from: <http://www.utdol.com/utd/index.do>.

2. Bajwa ZH, Smith HS. Overview of the treatment of chronic pain. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2012 [cited 2012 Oct]. Available from: <http://www.utdol.com/utd/index.do>.
3. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2012 [cited 2012 Oct]. Available from: <http://online.factsandcomparisons.com>.
4. Butrans[®] [package insert]. Stamford (CT): Purdue Pharma L.P.; 2012 Jul.
5. Embeda[®] (morphine sulfate/naltrexone) [package insert]. Bristol (TN): King Pharmaceuticals, Inc.; 2010 Jul.
6. Avinza[®] [package insert]. Bristol (TN): King Pharmaceuticals; 2012 Jul.
7. Dolophine[®] [package insert]. Columbus (OH): Roxane Laboratories, Inc.; 2012 Jul.
8. Exalgo[®] [package insert]. Vacaville (CA): ALZA Corporation; 2012 Aug.
9. Fentanyl patch [package insert]. Hazelwood (MO): Mallinckrodt Inc; 2012 Jul.
10. Kadian[®] [package insert]. Morristown (NJ): Actavis Elizabeth LLC; 2012 Jul.
11. Methadone solution [package insert]. Columbus (OH) Roxane Laboratories, Inc.; 2007 Sept.
12. Methadose[®] dispersible tablet and methadone tablet [package insert]. Hazelwood (MO): Mallinckrodt Inc; 2009 May.
13. Methadose[®] concentrate [package insert]. Hazelwood (MO): Mallinckrodt Inc; 2009 Oct.
14. Morphine sulfate extended-release tablet [package insert]. Wilson (NC): Purdue Pharmaceuticals, L.P.; 2012 Jul.
15. MS Contin[®] (morphine sulfate extended-release tablets) [package insert]. Stamford (CT): Purdue Pharma L.P.; 2009 Mar.
16. Nucynta[®] ER [package insert]. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2012 Jul.
17. Opana ER[®] [package insert]. Chadds Ford (PA): Endo Pharmaceuticals Inc.; 2012 Jul.
18. Oramorph SR[®] [package insert]. Newport (KY): Xanodyne Pharmaceuticals, Inc.; 2006 Feb.
19. Oxycontin[®] [package insert]. Stamford (CT): Purdue Pharma L.P.; 2012 Jul.
20. Central nervous system agents 28:00, analgesics and antipyretics 28:08, opiate agonists 28:08.08. In: McEvoy GK, editor; American Hospital Formulary Service. AHFS drug information 2012 [monograph on the Internet]. Bethesda (MD): American Society of Health-System Pharmacists; 2012 [cited 2012 Oct]. Available from: <http://online.statref.com>.
21. Medical Letter, Inc. Treatment guidelines from the Medical Letter: Drugs for Pain. 2010;8(92):25-34.
22. FDA Approves New Formulation for Oxycontin [press release on the internet]. Rockville (MD): Food and Drug Administration (US); 2010 Apr [cited 2012 Oct]. Available from: <http://www.fda.gov/newsevents/newsroom/PressAnnouncements/ucm207480.htm>.
23. Endo announces FDA approval of a new formulation of Opana[®] ER designed to be crush-resistant [press release on the internet]. Newark (DE): Endo Pharmaceuticals (US); 2011 Dec 12 [cited 2012 Oct]. Available from: <http://www.prnewswire.com/news-releases/endo-announces-fda-approval-of-a-new-formulation-of-opana-er-designed-to-be-crush-resistant-135431073.html>.
24. Butrans[®] (buprenorphine transdermal system) product dossier. May 5, 2011. Version 3.0. Purdue Pharma L.P. Data on file.
25. Ahmedzai S, Brooks D. Transdermal fentanyl vs sustained-release oral morphine in cancer pain; preference, efficacy, and quality of life. *J Pain Symptom Manage*. 1997;13:254-61.
26. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl vs sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. *Spine*. 2005;30(22):2484-90.
27. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. *Current Medical Research and Opinion*. 2004;20(9):1419-28.
28. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared to placebo in opioid-tolerant patients with chronic low back pain. *Curr Med Res Opin*. 2010;26(6):1505-18.
29. Hale M, Tudor IC, Khannas, Thippawong J. Efficacy and tolerability of once-daily OROS[®] hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a six-week, randomized, open-label, noninferiority analysis. *Clin Ther*. 2007;29(5):874-88.
30. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. *Palliative Medicine*. 2003;17:576-87.
31. Bruera E, et al. Methadone vs morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. *J Clin Oncol*. 2004;22(1):185-92.
32. Caldwell JR, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open label extension trial. *J Pain Symptom Manage*. 2002;23:278-91.
33. Allan L, Hays H, et al. Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. *BMJ*. 2001;322:1-7.
34. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. *Postgrad Med*. 2010 Jul;122(4):112-28.
35. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. *Neurology*. 2003;60:927-34.
36. Ma K, Jiang W, Zhou Q, Du DP. The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients. *Int J Clin Pract*. 2008;62(2):241-7.
37. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain*. 2003;105:71-8.
38. Bruera E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *Journal of Clinical Oncology*. 1998;16:3222-9.
39. Slatkin NE, Rhiner MI, Gould EM, Ma T, Ahdieh H. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer (abstract). *J Opioid Manag*. 2010;6(3):181-91.
40. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. *Support Care Cancer*. 2005;13:57-65.

41. Kivitz A, Ma C, Ahdieh H, Galer BS. A two-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. *Clinical Therapeutics*. 2006;38(3):352-64.
42. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of tapentadol extended release compared to oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. *Clin Drug Investig*. 2010;30(8):489-505.
43. Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. *Expert Opin Pharmacother*. 2010 Aug;11(11):1787-804.
44. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin*. 2011 Jan;27(1):151-62.
45. Madlung-Kratzer E, Spitzer B, Brosch R, Dunkel D, Haring C. A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release morphine vs methadone in opioid-dependent in-patients willing to undergo detoxification. *Addiction*. 2009;104:1,549-57.
46. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: adult cancer pain. Fort Washington (PA): 2012.version 1 [cited 2012 Oct]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.
47. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2008 Feb;10(2):113-30.
48. Questions and answers: FDA approves a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics [press release on the internet]. Rockville (MD): Food and Drug Administration (US); 2012 Jul 9 [cited 2012 Oct]. Available from: <http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm>.

**DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID
DRUG USE REVIEW (DUR) BOARD
PROPOSED PRIOR AUTHORIZATION CRITERIA**

Long-acting opioid analgesics exceeding the quantity limit are a covered benefit of Nevada Medicaid for recipients who meet the criteria for coverage.

1. Coverage and Limitations:

Authorization will be given if the following criteria are met and documented:

- a. The recipient is unable to achieve adequate analgesia despite attempts to titrate the dose of the long-acting opioid analgesic.
OR
- b. The requested dose cannot be obtained through dose consolidation of the long-acting opioid analgesic.
AND
- c. The requested quantity is being prescribed by a practitioner specializing in pain management.
OR
- d. There is documentation that the requested quantity is being prescribed after the recipient has had a consultation with a prescriber specializing in pain management.
AND
- e. The recipient is not currently receiving duplicate long-acting opioid analgesic therapy.

2. PA Guidelines:

Prior Authorization approval will be 6 months.

3. Quantity Limitations:

Butrans[®]: 4 patches of a single strength/28 days
Duragesic[®]: 15 patches of a single strength/30 days
Exalgo[®]: 30 capsules of a single strength/30 days
Avinza[®]: 30 capsules of a single strength/30 days
Kadian[®]: 60 capsules of a single strength/30 days
MS Contin[®]: 90 tablets of a single strength/30 days
Oramorph SR[®]: 90 tablets of a single strength/30 days
Oxycontin[®]: 90 tablets of a single strength/30 days
Opana ER[®]: 60 capsules of a single strength/30 days
Nucynta ER[®]: 60 capsules of a single strength/30 days